临床试验/NL-OMON45544

NL-OMON45544已完成不适用

A phase 1, randomized, double-blind, placebo-controlled study evaluating the pharmacokinetics of capsule and tablet formulations of VX-150, including the effects of food and milk, the relative bioavailability of the tablet formulation, and the drug-drug interaction between VX-150 and Midazolam, in healthy adults - A study to evaluate pharmacokinetics of VX-150 in healthy adults

Vertex Pharmaceuticals Incorporated0 个研究点目标入组 40 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方: Vertex Pharmaceuticals Incorporated
入组人数: 40

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 64（—）

入选标准

•- healthy male or femaile subjects
•- 18-55 yrs, inclusive
•- BMI: 18.0-31.0 kg/m2, inclusive

排除标准

•Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. Blood donation (of approximately 1 pint [500 mL] or more) within 56 days before the first dose of study drug, or any significant loss of blood, as determined by the investigator, within 60 days before the first dose of study drug.

研究者

发起方

Vertex Pharmaceuticals Incorporated

相似试验

A phase 1, randomized, double-blind, placebo-controlled, multiple dose platform study investigating the immunopharmacology of EDP1815 and EDP2939

NL-OMON51644Evelo Biosciences72

A phase 1, randomized, double-blind, placebo-controlled, single-dose escalation, multiple-dose escalation, and food effect study of RPT193 in healthy subjects and patients with moderate to severe atopic dermatitisatopische dermatitisAtopic dermititisasthma

NL-OMON49945RAPT Therapeutics, Inc.76

A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study evaluating safety and pharmacokinetics of VX-150 including an assessment of the effect of food on the pharmacokinetics of VX-150 in healthy adult subjects.Pijn.Pain.

NL-OMON41908Vertex Pharmaceuticals Incorporated96

A phase 1, randomized, double-blind, placebo-controlled, safety, tolerability, pharmacokinetic and biomarker study of multiple ascending doses of ESB1609 in healthy volunteers.

NL-OMON55239ESCAPE Bio, Inc.32

A phase 1, randomized, double-blind, placebo-controlled, sequential-panel, ascending single-dose study to evaluate the safety, tolerability, and pharmacokinetics of intravenous CMX-020 in healthy male and female subjects

ACTRN12617001583336Cytometix Inc48